secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001193125-25-244262
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients
--------------------------------------------------------------------------------

- Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.
- Enrollment exceeded initial target of ~20 patients, total 33 patients enrolled due to patient demand.
- Part B includes loading regimen (200mg weekly x4 then every other week) with 36-week dosing; topline data expected mid-2026.
- Preliminary PK data shows steady state achieved earlier with loading regimen; signs of clinical activity observed among early patients.
- Company plans to advance to pivotal trials pending Part B results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525244262/0001193125-25-244262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525244262/d43495d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-244262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer